GSK Q4 2025 Earnings Call Summary

1Key Financial Results and Metrics

Sales: Increased by 7% to over GBP 32 billion, driven by Specialty Medicines (+17%).

Core Operating Profit: Grew by 11%.

Earnings Per Share (EPS): Up 12%.

Cash Generation: Strong at GBP 8.9 billion, allowing for a dividend increase from 64p to 66p.

Research & Development (R&D): 5 FDA approvals and 7 new pivotal trial starts in 2025.

2Strategic Updates and Business Highlights

Focus Areas for 2026:

Maximize launch products like Blenrep and Exdensur.

Accelerate late-stage assets in oncology and respiratory diseases.

Enhance business development efforts, including the recent acquisition of Ozekibart for food allergies.

Specialty Medicines: Continued strong performance, with a forecast of low double-digit growth for 2026.

Vaccines: Sales of GBP 9.2 billion, up 2%, with Shingrix showing growth in Europe and international markets.

HIV Portfolio: Long-acting injectables driving growth, with Cabenuva sales up 42%. Upcoming Q6M treatment expected to significantly expand market share.

3Forward Guidance and Outlook

2026 Guidance:

Sales growth expected at 3% to 5%.

Core operating profit and EPS projected to grow by 7% to 9%.

Dividend forecasted at 70p, a 6% increase.

Product Area Expectations:

Specialty Medicines to lead growth.

Vaccines and General Medicines expected to see low single-digit declines or stabilize.

4Bad News, Challenges, or Points of Concern

Declining Metrics: Sales for ZEJULA decreased due to FDA labeling restrictions.

Vaccines: Anticipated low single-digit decline in Shingrix sales in the U.S. due to slowing immunization rates.

R&D Staff Reduction: Approximately 350 positions cut in the U.S. and U.K., raising concerns about resource allocation and focus.

Currency Headwinds: Expected negative impact on sales (-3%) and operating profit (-6%) if exchange rates remain stable.

5Notable Q&A Insights

COPD and Asthma Strategy: GSK is focusing on a diverse range of treatments for COPD, with a clear strategy to target different patient populations and avoid overlap in product positioning.

HIV Market Dynamics: Anticipated decline in sales due to loss of exclusivity for dolutegravir, but confidence in long-acting treatments to drive future growth.

Blenrep Launch: Initial uptake is slower due to the need for coordination with eye care professionals, but early feedback is positive. The launch is expected to ramp up gradually.

Financials of Q6M Treatment: Plans to include Q6M in long-term forecasts once Phase II trials commence, with expectations of significant market capture. Overall, GSK reported a strong performance in 2025 with a positive outlook for 2026, despite facing some challenges in specific product areas and market dynamics.